论文信息 - Impact of treatment delay in acute myeloid leukemia revisited.

Impact of treatment delay in acute myeloid leukemia revisited.

Gunnar Juliusson, Oskar Hagberg, Vladimir Lj Lazarevic, Sören Lehmann, and Martin Höglund, for the Swedish AML Registry Department of Hematology, Skåne University Hospital, Lund, Sweden; Department of Hematology, Stem Cell Center, Department of Laboratory Medicine, and Department of Cancer Epidemiology, Lund University, Lund, Sweden; Department of Medical Sciences, Uppsala University, Uppsala, Sweden; and Division of Hematology, Uppsala University Hospital, Uppsala, Sweden

G. Juliusson | V. Lazarevic | S. Lehmann | M. Höglund | O. Hagberg

[1] H. Einsele,et al. Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia? , 2020, Blood.

[2] L. Möllgård,et al. The prognostic impact of FLT3-ITD and NPM1 mutation in adult AML is age-dependent in the population-based setting. , 2020, Blood advances.

[3] L. Möllgård,et al. Improved survival of men 50 to 75 years old with acute myeloid leukemia over a 20-year period. , 2019, Blood.

[4] Daniel J Weisdorf,et al. Acute Myeloid Leukemia. , 2015, The New England journal of medicine.

[5] G. Laurent,et al. Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia. , 2013, Blood.

[6] Sören Lehmann,et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. , 2009, Blood.

[7] E. Estey,et al. Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients. , 2009, Blood.